JP2023501347A - アレルギー性疾患を治療するためのFcεRIβ及びMS4A6Aを組み合わせたエクソンスキップ - Google Patents

アレルギー性疾患を治療するためのFcεRIβ及びMS4A6Aを組み合わせたエクソンスキップ Download PDF

Info

Publication number
JP2023501347A
JP2023501347A JP2022526035A JP2022526035A JP2023501347A JP 2023501347 A JP2023501347 A JP 2023501347A JP 2022526035 A JP2022526035 A JP 2022526035A JP 2022526035 A JP2022526035 A JP 2022526035A JP 2023501347 A JP2023501347 A JP 2023501347A
Authority
JP
Japan
Prior art keywords
sequence
ms4a6a
fcεriβ
exon
antisense oligomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022526035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501347A5 (cg-RX-API-DMAC10.html
Inventor
ピー クルース グレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Carolina State University
Original Assignee
North Carolina State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina State University filed Critical North Carolina State University
Publication of JP2023501347A publication Critical patent/JP2023501347A/ja
Publication of JP2023501347A5 publication Critical patent/JP2023501347A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022526035A 2019-11-08 2020-11-09 アレルギー性疾患を治療するためのFcεRIβ及びMS4A6Aを組み合わせたエクソンスキップ Pending JP2023501347A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962932664P 2019-11-08 2019-11-08
US62/932,664 2019-11-08
PCT/US2020/059682 WO2021092562A1 (en) 2019-11-08 2020-11-09 Exon skipping of fc-epsilon-ri-beta and ms4a6a in combination for the treatment of allergic diseases

Publications (2)

Publication Number Publication Date
JP2023501347A true JP2023501347A (ja) 2023-01-18
JP2023501347A5 JP2023501347A5 (cg-RX-API-DMAC10.html) 2023-11-16

Family

ID=75849333

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526035A Pending JP2023501347A (ja) 2019-11-08 2020-11-09 アレルギー性疾患を治療するためのFcεRIβ及びMS4A6Aを組み合わせたエクソンスキップ

Country Status (6)

Country Link
US (1) US12637677B2 (cg-RX-API-DMAC10.html)
EP (1) EP4054639A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023501347A (cg-RX-API-DMAC10.html)
CN (1) CN115335078A (cg-RX-API-DMAC10.html)
AU (1) AU2020378207A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021092562A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136435A1 (en) 2016-02-01 2017-08-10 The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health Compounds for modulating fc-epsilon-ri-beta expression and uses thereof
CN112023062A (zh) * 2020-09-18 2020-12-04 北京基因安科技有限公司 一个用可溶性IgE受体抑制过敏反应的方法
JP2025531483A (ja) * 2022-09-28 2025-09-19 アタランタ セラピューティクス,インコーポレーテッド 神経炎症疾患の治療のための組成物及び方法
CN116219009B (zh) * 2022-10-19 2024-10-01 杭州师范大学 小胶质细胞特异性表达的ms4a6a在胶质母细胞瘤治疗或预后评估试剂盒上的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103074422A (zh) * 2012-12-29 2013-05-01 深圳市第三人民医院 Ms4a6a基因的用途
CN105969901A (zh) * 2016-07-27 2016-09-28 北京泱深生物信息技术有限公司 Ms4a6a作为多发性骨髓瘤诊治标志物的用途
WO2017136435A1 (en) * 2016-02-01 2017-08-10 The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health Compounds for modulating fc-epsilon-ri-beta expression and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989849A (en) 1991-05-09 1999-11-23 Temple University Of The Commonwealth System Of Higher Education Antisense of oligonucleotides to c-kit proto-oncogene and in vitro methods
US6806084B1 (en) 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
US20040137566A1 (en) * 2001-12-10 2004-07-15 Tedder Thomas F. Identification of novel ms4a gene family members expressed by hematopoietic cells
AU2005214287A1 (en) 2004-02-20 2005-09-01 Genesis Research And Development Corporation Limited Targeted delivery of RNA interference molecules for the treatment of IgE-mediated disorders
WO2005085443A2 (en) 2004-03-01 2005-09-15 Massachusetts Institute Of Technology Rnai-based therapeutics for allergic rhinitis and asthma
ES2627917T3 (es) 2004-06-28 2017-08-01 The University Of Western Australia Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos
EP2290088A1 (en) 2004-12-22 2011-03-02 Genentech, Inc. Methods for producing soluble multi-menbrane-spanning proteins
WO2007028065A2 (en) 2005-08-30 2007-03-08 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds for modulation of splicing
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
WO2009008727A2 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs or tissues
US8236557B2 (en) 2008-05-28 2012-08-07 University Of Missouri-Columbia Hybrid-AAV vectors to deliver large gene expression cassette
AU2010335039B2 (en) 2009-12-24 2015-03-26 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Molecule for treating an inflammatory disorder
ES2566553T3 (es) 2010-03-17 2016-04-13 Association Institut De Myologie ARNnp U7 modificados para el tratamiento de las enfermedades neuromusculares
EP3023496B1 (en) 2010-05-13 2020-07-29 Sarepta Therapeutics, Inc. Compounds which modulate interleukins 17 and 23 signaling activity
EP2500434A1 (en) 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
US20140080896A1 (en) 2011-08-30 2014-03-20 The Regents Of The University Of California Identification of small molecules that facilitate therapeutic exon skipping
DK2581448T3 (en) 2011-10-13 2015-04-27 Ass Inst De Myologie Tricyclo-DNA phosphorothioate
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
US9862945B2 (en) 2013-04-20 2018-01-09 Research Institute At Nationwide Children's Hospital Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
WO2016009487A1 (ja) 2014-07-14 2016-01-21 三菱電機株式会社 空気調和装置
EP3174981B1 (en) 2014-07-31 2020-03-25 Association Institut de Myologie Treatment of amyotrophic lateral sclerosis
EP2985343A1 (en) 2014-08-11 2016-02-17 Karlsruher Institut für Technologie In vitro-co-culturesystem
WO2019200383A1 (en) * 2018-04-13 2019-10-17 Ohio State Innovation Foundation Reagents and methods for autism and comorbidities thereof
EP3844278A4 (en) 2018-08-27 2022-05-25 North Carolina State University TARGETING KIT WITH SPLICE-SWITCHING OLIGONUCLEOTIDES FOR INDUCING APOPTOSIS OF MASTS CELLS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103074422A (zh) * 2012-12-29 2013-05-01 深圳市第三人民医院 Ms4a6a基因的用途
WO2017136435A1 (en) * 2016-02-01 2017-08-10 The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health Compounds for modulating fc-epsilon-ri-beta expression and uses thereof
CN105969901A (zh) * 2016-07-27 2016-09-28 北京泱深生物信息技术有限公司 Ms4a6a作为多发性骨髓瘤诊治标志物的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IMMUNOGENETICS, vol. 53, JPN6025021519, 2001, pages 357 - 368, ISSN: 0005822093 *
THE PROCEEDINGS OF THE NATIONALACADEMY OF SCIENCE, vol. 113, no. 49, JPN6025021518, 2016, pages 14115 - 14120, ISSN: 0005608722 *

Also Published As

Publication number Publication date
CN115335078A (zh) 2022-11-11
WO2021092562A1 (en) 2021-05-14
EP4054639A1 (en) 2022-09-14
AU2020378207A1 (en) 2022-06-23
US20220380777A1 (en) 2022-12-01
US12637677B2 (en) 2026-05-26
EP4054639A4 (en) 2025-04-30

Similar Documents

Publication Publication Date Title
US20230346928A1 (en) Mrna combination therapy for the treatment of cancer
JP6990176B2 (ja) メッセンジャーリボ核酸薬物の治療投与のための方法
US20230061936A1 (en) Methods of dosing circular polyribonucleotides
US20220380777A1 (en) Exon skipping of fc-epsilon-ri-beta and ms4a6a in combination for the treatment of allergic diseases
KR102825946B1 (ko) IL4Rα, TRPA1, 또는 F2RL1을 표적화하는 RNA 복합체를 사용한 아토피 피부염 및 천식의 치료
EP3430143B1 (en) Inhibitors of srsf1 to treat neurodegenerative disorders
US20190192691A1 (en) Regulated biocircuit systems
JP7479399B2 (ja) 癌腫瘍に対するテーラード低免疫ナノ小胞送達系
JP2024544760A (ja) 細胞及びウイルス受容体相互作用の中断によってasfv感染症を遮断する方法
CN112236130A (zh) 使用外排体对癌基因的治疗性靶向
CN114127301B (zh) 用于治疗肿瘤的药物组合物、药盒和方法
US20220372492A1 (en) Compounds for modulating fc-epsilon-ri-beta expression and uses thereof
CN118043461A (zh) 方法
WO2022022617A1 (en) Combinatory treatment of sma with sarna and mrna modulators
JPH09501057A (ja) 新規のオリゴヌクレオチド相互作用による血管細胞接着分子の発現の調節
CN113508175A (zh) 用于治疗癌症的组合物和方法
US20220290157A1 (en) Compositions and methods for treating amyotrophic lateral sclerosis
WO2021150770A1 (en) Oncogenic trim37 is a targetable epigenetic driver of metastasis and links chemoresistance and metastatic fate in triple-negative breast cancer
RU2839162C2 (ru) Молекула олигомерной нуклеиновой кислоты и ее применение
US20250368713A1 (en) Compositions, systems and methods for manipulating area postrema (ap) neurons based on gfral sensing
US20240425828A1 (en) Targeted retroviral integration for treatment of genetic disorders
PT1966368E (pt) Inibição do igf-1r mediada por arni para o tratamento da angiogénese ocular
Alavijeh et al. Advances in Genetic Medicine. Highlights from The Society for Medicines Research Online Meeting. Virtual-December 3, 2020
HK40092520A (en) Combinatory treatment of sma with sarna and mrna modulators
WO2026067818A1 (zh) 一种用于调控SCN1A基因mRNA和蛋白表达的方法和化合物

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230227

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260724